# SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer

> **NCT00005822** · PHASE1 · COMPLETED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 21 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** doxorubicin hydrochloride
- **DRUG:** semaxanib
- **PROCEDURE:** conventional surgery
- **RADIATION:** radiation therapy
- **DRUG:** tamoxifen

## Key facts

- **NCT ID:** NCT00005822
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-04
- **Primary completion:** 2002-12
- **Final completion:** 2003-10
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2010-06-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005822, "SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00005822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*